4/6
08:24 am
hind
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 [Yahoo! Finance]
Low
Report
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 [Yahoo! Finance]
4/6
08:00 am
hind
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
Low
Report
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
3/30
07:03 pm
hind
Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
Medium
Report
Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
3/26
08:00 am
hind
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Medium
Report
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
2/24
08:00 am
hind
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
Medium
Report
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
2/18
09:00 am
hind
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Neutral
Report
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
2/11
07:00 am
hind
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Medium
Report
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
2/2
07:00 am
hind
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
High
Report
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
1/27
08:00 am
hind
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
High
Report
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study